The benefits of antipsychotic medications are sometimes obscured by their adverse effects.
These effects range from relatively minor tolerability issues (eg, mild sedation or dry mouth) …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

The long‐term benefit‐to‐risk ratio of sustained antipsychotic treatment for schizophrenia
has recently been questioned. In this paper, we critically examine the literature on the long …

Background Tardive dyskinesia results from exposure to dopamine receptor antagonists,
such as typical and atypical antipsychotics. If clinically appropriate, clinicians often manage …

Introduction Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are stigmatizing
movement disorders associated with exposure to dopamine receptor blocking agents such …

Background Management of tardive syndromes (TS) is challenging, with only a few
evidence-based therapeutic algorithms reported in the American Academy of Neurology …

Background Tardive dyskinesia (TD) is a severe condition that can affect almost 1 out of 4
patients on current or previous antipsychotic treatment, including both first-generation …

Abstract Lower Urinary Tract Symptoms (LUTS) are frequently present in the general
population as patients age with approximately a third of individuals experiencing LUTS …

Tardive dyskinesia (TD), a movement disorder associated with antipsychotics, most
frequently affects the lower face and jaw muscles, but can also affect walking, breathing and …